시장보고서
상품코드
1150072

세계의 난소암 시장 점유율, 규모, 동향, 산업 분석 리포트 : 유형별, 진단별, 치료법별, 최종사용자별, 지역별, 부문 예측(2022-2030년)

Ovarian Cancer Market Share, Size, Trends, Industry Analysis Report, By Type ; By Diagnosis; By Therapeutic Treatment; By End-User; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 난소암 시장 규모는 2030년까지 96억 7,000만 달러에 달할 것으로 예측되고 있습니다.

세계의 난소암 시장에 대해 조사분석했으며, 시장 역학, 부문 분석, 지역 분석, 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 리포트 설명
    • 조사 목적
    • 시장 범위
    • 전제조건
  • 이해관계자

제2장 주요 요약

  • 시장 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 데이터 소스
    • 1차 소스
    • 2차 소스

제4장 세계의 난소암 시장 인사이트

  • 난소암 : 업계의 스냅숏
  • 난소암 시장 역학
    • 촉진요인과 기회
    • 억제요인과 과제
  • Porter's Five Forces 분석
    • 공급 기업의 교섭력(중)
    • 신규 참여업체의 위협(저)
    • 구매자의 교섭력(중)
    • 대체품의 위협(중)
    • 기존 기업간 경쟁력(고)
  • PESTLE 분석
  • 난소암 업계의 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 난소암 시장 : 진단별

  • 주요 조사 결과
  • 서론
    • 진단별 : 2018-2030년
  • 컴퓨터단층촬영(CT) 스캔
    • 컴퓨터단층촬영(CT) 스캔별
  • 초음파
    • 초음파별, 지역별 : 2018-2030년
  • 바륨 관장 X선
    • 바륨 관장 X선별, 지역별 : 2018-2030년
  • 자기공명영상법(MRI) 스캔
    • 자기공명영상법(MRI) 스캔별, 지역별 : 2018-2030년
  • 흉부 X선
    • 흉부 X선별, 지역별 : 2018-2030년
  • 양전자방출단층촬영법(PET) 스캔
    • 양전자방출단층촬영법(PET) 스캔별, 지역별 : 2018-2030년
  • 기타 진단 테스트
    • 기타 진단 테스트별, 지역별 : 2018-2030년

제6장 세계의 난소암 시장 : 치료법별

  • 주요 조사 결과
  • 서론
    • 치료법별 : 2018-2030년
  • 화학요법
    • 화학요법별, 지역별 : 2018-2030년
  • 방사선요법
    • 방사선요법별, 지역별 : 2018-2030년
  • 표적치료
    • 표적치료별, 지역별 : 2018-2030년
  • 호르몬 요법
    • 호르몬 요법별, 지역별 : 2018-2030년
  • 기타 치료법
    • 기타 치료법별, 지역별 : 2018-2030년
  • 수술
    • 수술별, 지역별 : 2018-2030년

제7장 세계의 난소암 시장 : 유형별

  • 주요 조사 결과
  • 서론
    • 유형별 : 2018-2030년
  • 상피성 종양
    • 상피성 종양별, 지역별 : 2018-2030년
  • 배세포종양
    • 배세포종양별, 지역별 : 2018-2030년
  • 간질성 종양
    • 간질성 종양별, 지역별 : 2018-2030년
  • 원발성 복막암
    • 원발성 복막암별, 지역별 : 2018-2030년

제8장 세계의 난소암 시장 : 최종사용자별

  • 주요 조사 결과
  • 서론
    • 최종사용자별 : 2018-2030년
  • 병원
    • 병원별, 지역별 : 2018-2030년
  • 진단 센터
    • 진단 센터별, 지역별 : 2018-2030년
  • 드러그스토어
    • 드러그스토어별, 지역별 : 2018-2030년
  • 온라인 약국
    • 온라인 약국별, 지역별 : 2018-2030년
  • 기타 최종사용자
    • 기타 최종사용자별, 지역별 : 2018-2030년

제9장 세계의 난소암 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 난소암 시장 평가 - 지역별 : 2018-2030년
  • 북미
    • 진단별 : 2018-2030년
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유형별 : 2018-2030년
    • 미국
    • 캐나다
  • 유럽
    • 진단별 : 2018-2030년
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유형별 : 2018-2030년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
  • 아시아태평양
    • 진단별 : 2018-2030년
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유형별 : 2018-2030년
    • 중국
    • 인도
    • 일본
    • 말레이시아
    • 인도네시아
    • 한국
  • 중동·아프리카
    • 진단별 : 2018-2030년
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유형별 : 2018-2030년
    • 사우디아라비아
    • 남아프리카공화국
    • 이스라엘
    • 아랍에미리트
  • 라틴아메리카
    • 진단별 : 2018-2030년
    • 최종사용자별 : 2018-2030년
    • 치료법별 : 2018-2030년
    • 유형별 : 2018-2030년
    • 멕시코
    • 브라질
    • 아르헨티나

제10장 경쟁 구도

  • 사업 확장과 인수 분석
    • 사업 확장
    • 인수
  • 제휴/협업/협정/전시회

제11장 기업 개요

  • AstraZeneca Inc.
  • Aetera Zenteris Inc
  • Bristol-Myers Squibb Corp
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Genentech Inc
  • Johnson & Johnson Corp
  • Janssen Pharmaceuticals, Inc.
  • Novogen, Inc
  • Oasmia Pharmaceutical Inc
  • Pfizer Inc
  • Roche Ltd.
  • Tesaro Inc.
KSA 22.11.18

The global ovarian cancer market is expected to reach USD 9.67 billion by 2030, according to a new study by Polaris Market Research. The report "Ovarian Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Epithelial Tumors, Germ Cell Tumors, Stromal Tumors, and Primary Peritoneal Cancer); By Diagnosis; By Therapeutic Treatment; By End-User; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market expansion is anticipated to be fueled by the growing emphasis on early diagnosis and treatment and rising FDA approvals for the treatment. The disease prognosis is still bleak because most patients only receive advanced-stage diagnoses. For instance, in November 2021, an imaging medication called Cytalux (pafolacianine), meant to help surgeons spot ovarian cancer lesions, received approval from the U.S. Food and Drug Administration. The medication makes it easier to find extra ovarian malignant tissue, which is typically challenging during surgery.

Further, in May 2020, the FDA authorized Lynparza in conjunction with bevacizumab as the initial maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or principal peritoneal cancer, according to an alliance from AstraZeneca and Merck. Therefore, there is a critical need for an in-depth study of disease biology to create potent therapeutic choices to overcome resistance and reduce toxicity.

The market is expected to be driven by increased government initiatives, rising R&D activities in cancer research, and the ease of use of new treatments and therapies. For instance, the Ovarian Cancer Research Alliance (OCRA), a non-profit group, focuses on cancer research and development. Top researchers at 79 eminent medical centers have received 349 grants totaling $110 million from OCRA, ensuring that research into ovarian cancer continues to advance the field and prepare the way for a solution. It funds several research initiatives aimed at identifying and treating this condition. Thus, these factors bolster industry growth during the forecast period.

Healthcare is expanding as a result of the rising economy of the nations in both developed and emerging regions. The industry is expected to continue to increase during the forecast period due to factors such as the rising incidence of ovarian cancer and the growing number of elderly women. According to the National Institute of Health, 604 million old women will exist worldwide by 2025.

Ovarian Cancer Market Report Highlights

Targeted therapy is anticipated to grow rapidly over the forecast period because it interfaces with specific proteins in tumorigenesis by focusing on molecular changes which stop the growth of various types of cancers. Also, targeted medicines are becoming more and more popular.

CT Scans segment accounted for a higher revenue share. Due to its capacity to shed light on tumor dissemination, CT scan demand in cancer diagnostics is anticipated to rise.

Asia-Pacific is expected to grow faster over the projected period due to the increasing prevalence of the geriatric population in emerging economies, improved healthcare infrastructure, rising disposable income, and increased consumer awareness regarding health.

The global market is highly competitive owing to the existence of significant players with a global presence, including AstraZeneca Inc., Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Corp., Janssen Pharmaceuticals, Inc., Novogen, Inc., Oasmia Pharmaceutical Inc, Pfizer Inc., Roche Ltd., and Tesaro Inc.

Polaris Market Research has segmented the Ovarian Cancer market report based on type, diagnosis, therapeutic treatment, end-user, and region:

Ovarian Cancer, Type Outlook (Revenue - USD Billion, 2018 - 2030)

Epithelial Tumors

Germ Cell Tumors

Stromal Tumors

Primary Peritoneal Cancer

Ovarian Cancer, Diagnosis Outlook (Revenue - USD Billion, 2018 - 2030)

Computed Tomography (C.T.) Scans

Ultrasound

Barium Enema X-Ray

Magnetic Resonance Imaging (MRI) Scans

Chest X-Ray

Positron Emission Tomography (PET) Scan

Other Diagnostic Tests

Ovarian Cancer, Therapeutic Treatment Outlook (Revenue - USD Billion, 2018 - 2030)

Chemotherapy

Radiation Therapy

Targeted Therapy

Hormone Therapy

Other Therapeutic Treatments

Surgery

Ovarian Cancer, End-User Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Diagnostic Centers

Drug Stores

Online Pharmacies

Other End Users

Ovarian Cancer, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Ovarian Cancer Market Insights

  • 4.1. Ovarian Cancer - Industry Snapshot
  • 4.2. Ovarian Cancer Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in the Elderly women's population
      • 4.2.1.2. Rising healthcare awareness is accelerating the market
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Ignorance of the symptoms of Ovarian Cancer may drag down the market
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Ovarian Cancer Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Ovarian Cancer Market, by Diagnosis

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
  • 5.3. Computed Tomography (C.T.) Scans
    • 5.3.1. Global Ovarian Cancer Market, by Computed Tomography (C.T.) Scans, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Ultrasound
    • 5.4.1. Global Ovarian Cancer Market, by Ultrasound, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Barium Enema X-Ray
    • 5.5.1. Global Ovarian Cancer Market, by Barium Enema X-Ray, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Magnetic Resonance Imaging (MRI) Scans
    • 5.6.1. Global Ovarian Cancer Market, by Magnetic Resonance Imaging (MRI) Scans, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Chest X-Ray
    • 5.7.1. Global Ovarian Cancer Market, by Chest X-Ray, by Region, 2018 - 2030 (USD Billion)
  • 5.8. Positron Emission Tomography (PET) Scan
    • 5.8.1. Global Ovarian Cancer Market, by Positron Emission Tomography (PET) Scan, by Region, 2018 - 2030 (USD Billion)
  • 5.9. Other Diagnostic Tests
    • 5.9.1. Global Ovarian Cancer Market, by Other Diagnostic Tests, by Region, 2018 - 2030 (USD Billion)

6. Global Ovarian Cancer Market, by Therapeutic Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Ovarian Cancer Market, by Chemotherapy, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Radiation Therapy
    • 6.4.1. Global Ovarian Cancer Market, by Radiation Therapy, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Targeted Therapy
    • 6.5.1. Global Ovarian Cancer Market, by Targeted Therapy, by Region, 2018 - 2030 (USD Billion)
  • 6.6. Hormone Therapy
    • 6.6.1. Global Ovarian Cancer Market, by Hormone Therapy, by Region, 2018 - 2030 (USD Billion)
  • 6.7. Other Therapeutic Treatments
    • 6.7.1. Global Ovarian Cancer Market, by Other Therapeutic Treatments, by Region, 2018 - 2030 (USD Billion)
  • 6.8. Surgery
    • 6.8.1. Global Ovarian Cancer Market, by Surgery, by Region, 2018 - 2030 (USD Billion)

7. Global Ovarian Cancer Market, by Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.3. Epithelial Tumors
    • 7.3.1. Global Ovarian Cancer Market, by Epithelial Tumors, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Germ Cell Tumors
    • 7.4.1. Global Ovarian Cancer Market, by Germ Cell Tumors, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Stromal Tumors
    • 7.5.1. Global Ovarian Cancer Market, by Stromal Tumors, by Region, 2018 - 2030 (USD Billion)
  • 7.6. Primary Peritoneal Cancer
    • 7.6.1. Global Ovarian Cancer Market, by Primary Peritoneal Cancer, by Region, 2018 - 2030 (USD Billion)

8. Global Ovarian Cancer Market, by End-User

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
  • 8.3. Hospitals
    • 8.3.1. Global Ovarian Cancer Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Diagnostic Centers
    • 8.4.1. Global Ovarian Cancer Market, by Diagnostic Centers, by Region, 2018 - 2030 (USD Billion)
  • 8.5. Drug Stores
    • 8.5.1. Global Ovarian Cancer Market, by Drug Stores, by Region, 2018 - 2030 (USD Billion)
  • 8.6. Online Pharmacies
    • 8.6.1. Global Ovarian Cancer Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 8.7. Other End Users
    • 8.7.1. Global Ovarian Cancer Market, by Other End Users, by Region, 2018 - 2030 (USD Billion)

9. Global Ovarian Cancer Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Ovarian Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Ovarian Cancer Market - North America
    • 9.3.1. North America: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.3.5. Ovarian Cancer Market - U.S.
      • 9.3.5.1. U.S.: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.3.6. Ovarian Cancer Market - Canada
      • 9.3.6.1. Canada: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4. Ovarian Cancer Market - Europe
    • 9.4.1. Europe: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.4.5. Ovarian Cancer Market - UK
      • 9.4.5.1. UK: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.4.6. Ovarian Cancer Market - France
      • 9.4.6.1. France: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.4.7. Ovarian Cancer Market - Germany
      • 9.4.7.1. Germany: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.4.8. Ovarian Cancer Market - Italy
      • 9.4.8.1. Italy: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.4.9. Ovarian Cancer Market - Spain
      • 9.4.9.1. Spain: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.4.10. Ovarian Cancer Market - Netherlands
      • 9.4.10.1. Netherlands: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.4.11. Ovarian Cancer Market - Russia
      • 9.4.11.1. Russia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.5. Ovarian Cancer Market - Asia Pacific
    • 9.5.1. Asia Pacific: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.5.5. Ovarian Cancer Market - China
      • 9.5.5.1. China: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.5.6. Ovarian Cancer Market - India
      • 9.5.6.1. India: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.5.7. Ovarian Cancer Market - Japan
      • 9.5.7.1. Japan: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.5.8. Ovarian Cancer Market - Malaysia
      • 9.5.8.1. Malaysia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.5.9. Ovarian Cancer Market - Indonesia
      • 9.5.9.1. Indonesia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.5.10. Ovarian Cancer Market - South Korea
      • 9.5.10.1. South Korea: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.6. Ovarian Cancer Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.6.5. Ovarian Cancer Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.6.6. Ovarian Cancer Market - South Africa
      • 9.6.6.1. South Africa: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.6.7. Ovarian Cancer Market - Israel
      • 9.6.7.1. Israel: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.6.8. Ovarian Cancer Market - UAE
      • 9.6.8.1. UAE: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.7. Ovarian Cancer Market - Latin America
    • 9.7.1. Latin America: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.7.5. Ovarian Cancer Market - Mexico
      • 9.7.5.1. Mexico: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.7.6. Ovarian Cancer Market - Brazil
      • 9.7.6.1. Brazil: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 9.7.7. Ovarian Cancer Market - Argentina
      • 9.7.7.1. Argentina: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. AstraZeneca Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Aetera Zenteris Inc
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bristol-Myers Squibb Corp
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Boehringer Ingelheim GmbH
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Eli Lilly and Company
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. GlaxoSmithKline plc
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Genentech Inc
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Johnson & Johnson Corp
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Janssen Pharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Novogen, Inc
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Oasmia Pharmaceutical Inc
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Pfizer Inc
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Roche Ltd.
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Tesaro Inc.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제